{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ebe8cc563e3d811bbd2c9d8/60eff581dd8c200013643dd7?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"How to treat first relapse in lenalidomide-refractory MM? ","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5ebe8cc563e3d811bbd2c9d8/1589546617002-fe8127d1b39ab8ac94a64885bbfaa0ae.jpeg?height=200","description":"<p>During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Clifton C. Mo and Omar Nadeem, Dana-Farber Cancer Institute, Boston, US. We asked, How to treat first relapse in lenalidomide-refractory multiple myeloma (MM)?</p><p><br></p><p>In this podcast, Mo and Nadeem discuss factors to be considered with regimen options for patients with lenalidomide-refractory MM. They discuss cardiac risk factors, lines of therapy, prognosis, and end the podcast on the topic of new agents.</p>","author_name":"Scientific Education Support"}